Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

34.52
-0.1200-0.35%
Post-market: 34.940.4200+1.22%17:55 EDT
Volume:6.91M
Turnover:238.47M
Market Cap:24.94B
PE:-73.45
High:34.95
Open:34.64
Low:34.26
Close:34.64
52wk High:37.97
52wk Low:11.94
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.55
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.89
PE(LYR):-63.93

Loading ...

Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905

Reuters
·
Aug 29

Roivant Sets Price for New Rare Disease Drug Lisraya at $35,000 a Month

Reuters
·
Aug 28

Lisraya is Commercially Available NOW - Roivant Presentation

THOMSON REUTERS
·
Aug 28

Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply

THOMSON REUTERS
·
Aug 28

Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 28

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

MT Newswires Live
·
Aug 28

Priovant Therapeutics - Lisraya NOW Available in the U.S.

THOMSON REUTERS
·
Aug 28

Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.

THOMSON REUTERS
·
Aug 28

US FDA Approves Roivant-Priovant's Skin Disease Drug

Reuters
·
Aug 28

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Reuters
·
Aug 28

FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis

THOMSON REUTERS
·
Aug 28

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Reuters
·
Aug 26

Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Aug 26

Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $12.47 Million

Reuters
·
Aug 22

Roivant President, CIO Mayukh Sukhatme Disposes of USD 24.12 Million in Common Shares

Reuters
·
Aug 19

Roivant Sciences (ROIV) Receives a Buy from Jefferies

TIPRANKS
·
Aug 18

Citi Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
Aug 10

Roivant Sciences Ltd : Citigroup Raises Target Price to $46 from $42

THOMSON REUTERS
·
Aug 10

Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
Aug 07

Roivant Sciences is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07